Zenitar

Zenitar (赜灵生物) is a Chinese biopharmaceutical company founded by Professor Chen Lijuan (陈俐娟), and elsewhere's corpus covers it mainly through its funding announcements . In August 2025 it raised a B+ round of nearly 400 million yuan led by Qiming Venture Partners — closed, as Chen put it, against a backdrop of cooling capital markets and slowing biotech financing . By January 2026 it had followed up with a Series C of nearly 600 million yuan, co-led by Temasek's wholly-owned Danming Capital and Qiming, with Tencent Investment, BlueRun Ventures, Jianfa Xinxing Venture Capital and the Shanghai Science and Technology Innovation Fund participating, and existing shareholders including 5Y Capital, Huajin Capital, Guosheng Capital and Sichuan Science and Technology Investment Group adding to their positions . Per BlueRun Ventures, the Series C proceeds are earmarked for global clinical development, pipeline expansion and technology platform upgrades . Beyond the funding trail, elsewhere's corpus has little on Zenitar's specific therapeutic focus or science.